Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOcuphire Pharma Inc

Ocuphire Pharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.98 USD -0.15 ( 13.27%)
Last update at 2024-11-20T14:30:00Z
VOLUME
209862
Market Cap
45.63M

Momentum Score

…

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.91
Low
0.98
High
52 Week Price Range
1.50
Low
4.58
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.13
Dividend Yield
-
Revenue TTM
19.01M
Revenue Per Share
0.84
Gross Profit TTM
-14.58M
Debt / Equity
0.02
ROE
-25.89%
Net Debt
-50.50M
ROCE
36.52%
Diluted EPS TTM
-0.47

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 18.20M -56.69M -24.62M -6.17M -14.37M
Net income 17.89M -56.53M -31.48M -7.51M -14.37M
Selling general administrative 7.27M 8.12M 2.82M 1.82M 7.43M
Gross profit 39.85M 0.59M - - -
Reconciled depreciation 0.00M 0.00M 0.01M 0.00M -
Ebit 18.23M -22.70M -19.97M -4.19M -1.30M
Ebitda 18.21M -22.86M -9.45M -4.26M -20.54M
Depreciation and amortization -0.01M -0.16M 10.52M -0.07M -
Operating income 18.23M -22.70M -19.97M -4.19M -20.54M
Other operating expenses 21.62M 23.29M 9.47M 4.19M 20.54M
Interest expense 0.01M 0.00M 6.85M 1.41M 0.00M
Tax provision 0.32M 0.00M 0.00M 0.00M -
Net interest income -0.01M -0.00M -6.85M -1.41M -
Income tax expense 0.32M -0.16M 6.86M 1.34M -
Total revenue 39.85M 0.59M 0.00M 0.00M -
Total operating expenses 21.62M 23.29M 9.47M 4.19M 20.54M
Total other income expense net -0.02M -33.99M -4.65M -1.98M 6.17M
Net income from continuing ops 17.89M -56.69M -24.62M -6.17M -
Net income applicable to common shares 17.89M -56.69M -24.62M -6.17M -1.63M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 53.95M 48.99M 26.08M 17.68M 1.78M
Other current assets 1.10M 1.45M 1.31M 0.03M 0.01M
Total liab 4.04M 2.75M 3.85M 31.15M 9.34M
Total stockholder equity 49.91M 46.24M 22.22M -13.47M -7.56M
Other current liab 1.89M 1.68M 1.73M 1.97M 2.71M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -81.47M -71.48M -89.37M -32.67M -8.05M
Other liab - - - 27.96M -
Cash 50.50M 42.63M 24.53M 16.40M 1.54M
Total current liabilities 4.04M 2.75M 3.85M 3.19M 9.34M
Current deferred revenue - - - - 0.62M
Net debt -50.50M -42.63M -24.00M -16.40M 4.13M
Short term debt - - 0.54M 5.67M 5.67M
Short long term debt - - 0.54M - 5.67M
Short long term debt total - - 0.54M - 5.67M
Other stockholder equity 131.37M 117.72M 111.59M 19.21M 0.49M
Property plant equipment - 0.01M 0.01M 0.01M 0.02M
Total current assets 53.95M 48.99M 26.07M 17.67M 1.76M
Net tangible assets - 46.24M 22.22M -13.47M -7.56M
Short term investments 0.01M 0.05M 0.22M - 3.00M
Net receivables 2.33M 4.85M - - 0.12M
Inventory - - - - 0.10M
Accounts payable 2.15M 1.07M 1.58M 1.21M 0.34M
Accumulated other comprehensive income 0.00M - - - 0.00M
Common stock total equity - - - 0.00M -
Non current assets total 0.00M 0.01M 0.01M 0.01M 0.02M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00M -0.10M 0.54M -0.03M -
Change to liabilities 0.00M 0.38M 0.79M -0.17M 0.38M
Total cashflows from investing activities - -0.10M 0.54M -0.03M -0.03M
Net borrowings - 0.54M 2.20M 4.71M 1.23M
Total cash from financing activities 3.79M 27.61M 21.12M 4.70M 6.77M
Change to operating activities - -0.20M 0.35M 0.53M 0.09M
Net income 17.89M -56.69M -24.62M -6.17M -14.37M
Change in cash 18.10M 8.13M 14.86M 1.09M -0.15M
Begin period cash flow 24.53M 16.40M 1.54M 0.45M 8.90M
End period cash flow 42.63M 24.53M 16.40M 1.54M 8.74M
Total cash from operating activities 14.31M -19.37M -6.80M -3.59M -18.84M
Issuance of capital stock 4.43M 28.49M 21.15M 0.00M -
Depreciation 0.00M 0.00M 0.01M 0.00M 0.09M
Dividends paid - - - - 0.00M
Change to account receivables -1.30M - - - -
Other cashflows from financing activities -0.10M -0.78M -0.03M -2.95M -0.10M
Change to netincome - 37.14M 15.72M 1.10M 0.26M
Capital expenditures 0.00M 0.10M 1.48M 0.03M 0.03M
Change in working capital -5.55M 0.18M 1.15M 0.36M -0.08M
Stock based compensation 1.81M 1.91M 1.51M 0.31M 1.23M
Other non cash items 0.17M 1.61M 16.66M 1.41M -5.79M
Free cash flow 14.31M -19.37M -6.80M -3.62M -18.84M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OCUP
Ocuphire Pharma Inc		 -0.15
13.27%		 0.98 - 12.00 2.40 0.92 1.39 -2.66
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Ocuphire Pharma Inc

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

37000 Grand River Avenue, Farmington Hills, MI, United States, 48335

(248) 957-9024

https://www.ocuphire.com

14

Name Title Year Born
Ms. Mina Patel Sooch M.B.A., MBA Founder, CEO, Pres, Treasurer & Vice Chair of the Board 1968
Ms. Amy Zaremba Rabourn C.P.A., CPA, MAcc VP of Fin. & Principal Accounting Officer 1981
Mr. Bernhard Hoffmann M.B.A. VP of Corp. Devel. & Operations and Sec. 1956
Dr. Daniela C. Oniciu Ph.D. Global Head of R&D, Chemistry and Product Devel. NA
Dr. Mitchell Brigell Ph.D. Head of Clinical Devel. & Strategy NA
Mr. Chris Ernst Global Head of QA & Manufacturing NA
Ms. Bindu Manne Head of Market Devel. & Commercialization NA
Mr. Erik Sims Director & Corp. Controller NA
Mr. Richard J. Rodgers M.B.A. Interim President & Director 1967
Mr. Bernhard Hoffmann M.B.A. Senior Vice President of Corporate Development & Operations and Secretary 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…